Press Releases

Elgan Pharma, a late-stage clinical biopharmaceutical company focusing on innovative treatments for critical conditions in neonates, announced today that it has been awarded by the European Innovation Council (EIC) a grant of €2.36 million ($2.5 million) in a highly competitive selection process. The grant will support the Phase III registrational study of ELGN-GI, an innovative oral formulation for the treatment of intestinal malabsorption, that causes feeding intolerance in preterm inf

Kintor Pharmaceutical Limited a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be

PromoCell, a leading manufacturer of cell culture products, announced the launch of PromoExQ MSC Growth Medium XF, a serum- and xeno-free cell culture medium designed for GMP compliant isolation and expansion of mesenchymal stem cells (MSCs) for cell therapy manufacturing applications. PromoExQ MSC Growth Medium XF enables the isolation and expansion of a variety of MSC types, including MSCs from the bone marrow, umbilical cord matrix, and adipose tissue, and ensures their consisten

DTx Pharma, invested and incubated by Viva BioInnovator is a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide platform. Recently they announced that it has been acquired by Novartis. The FALCON platform enables the delivery and activity of small interfering RNA (siRNA) therapeutics to tissues beyond the liver, enhancing biodistribution and cellular uptake. DTx Pharma's lead prog

Biostage, Inc. a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects initially in the esophagus and the airway, today announced that it officially activated the site with Mayo Clinic for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States. "We are thrilled to announce the initiation of our first clinical study f

PrecisionLife, a leading computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This analysis opens the door for new precision diagnostic and therapeutic approaches to address the massive unmet medical need affecting the lives of millio

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients.  It was published online at the American Society of Clinical Oncology (ASCO) Annual Meeting. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid. The ASCO meeting is June 2 – 6, 2

WuXi STA – a global Contract Research, Development, and Manufacturing Organization launches a first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China. The new HP injectable manufacturing line, with an annual capacity of 12 million units, further enhances the company’s manufacturing capabilities and capacity for injectable dosage forms – providing greater flexibility to respond to the increasing demand of the

Genomic Vision, a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard. HexaCard is a powerful solution for the control and optimization of genome editing, mainly used in gene therapy and biomanufacturing applications. The service addresses the prevalent challenges of cellular cross-contamination, misidentified cell lines, and the use of cell

Lonza has launched the TheraPRO® CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines. The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time-to-market. The versatility and efficiency of antibody therapeutics continues to transform the healthcare industry. To meet growing demand fo